Shionogi said on October 23 that it has lifted its first-half earnings forecast as robust PIII data for its sakigake-designated flu drug S-033188 has prompted a revision to a milestone arrangement with its global partner Roche, which resulted in an…
To read the full story
Related Article
- Shionogi’s Net Profit Crosses 100 Billion Yen Mark in FY2017
May 10, 2018
- Shionogi Notches Double-Digit Sales Rise on HIV/Flu Royalties
October 31, 2017
BUSINESS
- Japan Pharma Market Up 1.7% in 2025, 5th Straight Year of Growth: IQVIA
February 26, 2026
- Sawai to End Teribone Generic Sales following Patent Settlement
February 26, 2026
- Darzquro Seen as Emerging Standard in High-Risk SMM: Specialist
February 26, 2026
- Towa Wins Pediatric Autism Use for Abilify Generic
February 26, 2026
- Jardiance Tops Five Promotion Channels in January: Intage
February 26, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





